Conformation of Beta Human Chorionic Gonadotropin During Chemotherapy for Choriocarcinoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2006 by National Taiwan University Hospital.
Recruitment status was  Not yet recruiting
Sponsor:
Collaborator:
National Science Council, Taiwan
Information provided by:
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT00294177
First received: February 17, 2006
Last updated: NA
Last verified: February 2006
History: No changes posted
  Purpose

Gestational trophoblastic disease comprises a spectrum of diseases with different propensity for local invasion and metastasis, that is, partial and complete hydatidiform mole, choriocarcinoma, and placental site trophoblastic tumor.All trophoblastic tumors produce hCG, and monitoring of therapy is largely based on the determination of hCG in serum. The conformational change of tumor markers during antineoplastic chemotherapy for cancer and its clinical meaning has only been rarely studied. In this study, we will try to understand the conformational change of the tumor marker (hCG) during chemotherapy.


Condition Intervention Phase
Trophoblastic Neoplasms
Choriocarcinoma
Device: atomic force microscopy
Device: dual polarisation interferometry
Phase 4

Study Type: Observational
Study Design: Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Cross-Sectional
Official Title: Conformation of Beta Human Chorionic Gonadotropin During Chemotherapy for Persistent Gestational Trophoblastic Tumors Using Atomic Force Microscopy and Dual Polarisation Interferometry

Resource links provided by NLM:


Further study details as provided by National Taiwan University Hospital:

Estimated Enrollment: 30
Study Start Date: August 2006
Estimated Study Completion Date: July 2008
  Show Detailed Description

  Eligibility

Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinical diagnosis of trophoblastic neoplasms
  • Willing to be collected for the urine and 2 ml blood samples

Exclusion Criteria:

  • Unwilling to be collected for the collect urine or 2ml blood sample
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00294177

Contacts
Contact: Ruey-Jien Chen, MD, PhD 886-2-23123456 ext 5158 rjchen@ha.mc.ntu.edu.tw

Locations
Taiwan
National Taiwan University Hospital Department of Obstetrics and Gynecology Not yet recruiting
Taipei, Taiwan, 100
Contact: Ruey-Jien Chen, MD, PhD    886-2-2312-3456 ext 5158    rjchen@ha.c.ntu.edu.tw   
Principal Investigator: Ruey-Jien Chen, MD, PhD         
Sponsors and Collaborators
National Taiwan University Hospital
National Science Council, Taiwan
Investigators
Principal Investigator: Ruey-Jien Chen Department or Obstetrics and Gynecology, National Taiwan university Hospital
  More Information

Additional Information:
Publications:
ClinicalTrials.gov Identifier: NCT00294177     History of Changes
Other Study ID Numbers: 9561702010, Taiwan NSC 94WFA0101857
Study First Received: February 17, 2006
Last Updated: February 17, 2006
Health Authority: Taiwan: Department of Health

Keywords provided by National Taiwan University Hospital:
Trophoblastic Neoplasms
Chorionic Gonadotropin
Molecular Conformation

Additional relevant MeSH terms:
Gestational Trophoblastic Neoplasms
Neoplasms
Choriocarcinoma
Trophoblastic Neoplasms
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Pregnancy Complications, Neoplastic
Pregnancy Complications
Chorionic Gonadotropin
Reproductive Control Agents
Physiological Effects of Drugs
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on July 24, 2014